ArticleFrontiers in neurology2020
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05808101 (Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects), which is not on this map. Cited by 52 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 5 pooled it
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects
Who cites it
52 citing papers in PubMed, 5 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Effectiveness of technology-based exercise on motor function and quality of life in individuals with multiple sclerosis: an umbrella review.Journal of health, population, and nutrition · 2025Pooled it
- The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Implementation strategies and outcome measures for advancing learning health systems: a mixed methods systematic review.Health research policy and systems · 2023Pooled it
- The Minimum Data Set for Rare Diseases: Systematic Review.Journal of medical Internet research · 2023Pooled it
- Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Pooled it
- Reconciling global collaboration and data sovereignty in neuroscience.Nature neuroscience · 2026Review
- Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.Annals of neurology · 2026Article
- Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Assessing the cervical canal area in multiple sclerosis with spinal cord sagittal 2D T2-weighted sequences.Magma (New York, N.Y.) · 2026Article
- Serum metabolomic-lipidomic signatures track long-term neurological performance in multiple sclerosis.Molecular neurodegeneration advances · 2026Article
- Article
- Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.Neurodegenerative disease management · 2025Article
- AI-driven reclassification of multiple sclerosis progression.Nature medicine · 2025Article
- The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study.The Lancet regional health. Europe · 2025Article
- Digital Biomarkers and AI for Remote Monitoring of Fatigue Progression in Neurological Disorders: Bridging Mechanisms to Clinical Applications.Brain sciences · 2025Article
- Observational
- Metabolic and lipid alterations in multiple sclerosis linked to disease severity.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.Neurodegenerative disease management · 2025Article
- Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis.Brain communications · 2025Article
- Deep learning to predict progression independent of relapse activity at a first demyelinating event.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 12 institutions in 3 countries.
Ellen M MowryJohns Hopkins University, Baltimore, MD, United States.
Robert A BermelCleveland Clinic, Cleveland, OH, United States.
James R WilliamsBiogen, Cambridge, MA, United States.
Tammie L S BenzingerWashington University in St. Louis, St. Louis, MO, United States.
Carl de MoorBiogen, Cambridge, MA, United States.
Elizabeth FisherBiogen, Cambridge, MA, United States.
Carrie M HershCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States.
Megan H HylandUniversity of Rochester Medical Center, Rochester, NY, United States.
Izlem IzbudakJohns Hopkins University, Baltimore, MD, United States.
Stephen E JonesCleveland Clinic, Cleveland, OH, United States.
Bernd C KieseierBiogen, Cambridge, MA, United States.
Hagen H KitzlerCenter of Clinical Neuroscience, University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.
Lauren KruppNew York University, New York, NY, United States.
Yvonne W LuiNew York University, New York, NY, United States.
Xavier MontalbanVall d'Hebron University Hospital, Barcelona, Spain.
Robert T NaismithWashington University in St. Louis, St. Louis, MO, United States.
Jacqueline A NicholasOhioHealth, Columbus, OH, United States.
Fabio PellegriniBiogen, Cambridge, MA, United States.
Alex RoviraVall d'Hebron University Hospital, Barcelona, Spain.
Maximilian SchulzeUniversity Hospital of Giessen and Marburg, Marburg, Germany.
Björn TackenbergUniversity Hospital of Giessen and Marburg, Marburg, Germany.
Mar TintoreVall d'Hebron University Hospital, Barcelona, Spain.
Madalina E TivarusUniversity of Rochester Medical Center, Rochester, NY, United States.
Tjalf ZiemssenCenter of Clinical Neuroscience, University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.
Richard A RudickBiogen, Cambridge, MA, United States.
Biogen (United States) · USVall d'Hebron Hospital Universitari · ESCleveland Clinic · USJohns Hopkins University · USNew York University · USUniversitätsklinikum Gießen und Marburg · DEUniversity of Rochester Medical Center · USWashington University in St. Louis · USLou Ruvo Brain Institute · USOhioHealth · USTU Dresden · DEUniversity Hospital Carl Gustav Carus · DE
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5MNIA NIH HHS P01 AG003991
Abstract
PubMed holds no abstract for this paper.
Indexed as
digital health technologylearning health systemMS PATHSmultiple sclerosisstandardized brain magnetic resonance imaging
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05808101ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.